

Press Release

Portfolio company Biolinq Incorporated granted De Novo Classification by U.S. FDA for its lead product

AXA IM Alts, a global leader in alternative investments with over €188 billion of assets under management, is pleased to announce its portfolio company Biolinq Incorporated ('Biolinq') has been granted De Novo classification by the U.S. Food and Drug Administration for its lead product Biolinq Shine™.

Biolinq is a developer of precision multi-analyte biosensors to improve metabolic health. Fully autonomous and needle-free, its glucose sensor will be initially marketed to people with type 2 diabetes who are not dependent on insulin. The U.S. Food and Drug Administration decision to grant De Novo classification marks a significant milestone for the company and unlocks the potential for scalable growth of a new generation of wearable glucose sensors.

Directly aligned with the United Nations' Sustainable Development Goal 3: Good Health and Wellbeing, the support from AXA IM Alts' global healthcare private equity strategy and impact investments has boosted Biolinq's development in the market.

Dr Zina Affas Besse, Deputy Head of Healthcare Private Equity at AXA IM Alts, comments: "We are proud to see Biolinq granted De Novo classification by U.S. FDA for its intradermal glucose sensor, which marks a major milestone in its mission to address metabolic health. This aligns with AXA IM Alts' goals to invest in solutions that contribute to improve global health, while also aiming to generate attractive financial returns."

The strategy can be exposed to the following risks: liquidity risk, valuation risk, sourcing/operational risk, market risk and of capital loss.

The investment identified does not represent all of the investments purchased, sold, or recommended for the strategy. There is no guarantee that the investment we make were or will be profitable. Developments of the past offer no guarantee and are no indicator for any future returns or trends.

Capital at risk. The value of investments may fall as well as rise and you may not get back the full amount invested.

- END -

Notes to editors

All figures at end-June 2025.

Biolinq Shine™ device has received De Novo classification from the FDA, officially designating it as a Class II medical device and enabling its commercial availability for patient use under prescription. The De Novo pathway is a regulatory process used by the FDA to classify novel medical devices that have no existing predicate and are deemed to have low or moderate risk.

<https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/de-novo-classification-request#What is a De Novo Classification Request>

Press contacts

Jocelyne Tamssom - +33 1 44 45 96 62

Pauline Mauvenu - +33 1 44 45 89 84

PressOfficeAXAIMAlts@axa-im.com

FTI Consulting Inc.

Richard Sunderland, Ambrose Fullalove, Lynn Begany, Lottie Pearson

Tel: +44 7753 302 269

AXAIMAltsAC@FTIConsulting.com

About AXA IM Alts

AXA IM Alts is a business unit of AXA Investment Managers, part of the **BNP Paribas Group** since **1st July 2025** following the closing of its acquisition.

AXA IM Alts is a **global leader in alternative investments** with over €188 billion of assets under management comprising over €80 billion of primarily **private real estate**, €96 billion of **private debt and alternative credit**, as well as over €12 billion in **Infrastructure** and **private equity**.

We take a 360° approach to real estate & infrastructure investing with over €126 billion of assets under management in **direct opportunities, held indirectly through debt and listed equities** and via **long term private equity investments** into operating platforms. ESG is fully integrated into our investment decision making processes with a particular focus on decarbonization.

AXA IM Alts employs over 990 people located in 17 offices around the world and serves the needs of over 600 clients from Europe, North America, Asia Pacific and Middle East. We are the **number one property portfolio and asset manager in Europe, and one of the largest worldwide**.

All figures at end-June 2025

Highest-ranked Real Estate Manager in the European Union according to IPE's Global Top 150 Real Estate Investment Managers, based on total value of real estate assets under management, November/December 2024

Visit our websites: <https://alts.axa-im.com> and www.axa-im.com

Visit our media centre: <https://alts.axa-im.com/media-centre>

Follow us on: [LinkedIn](#)

This document is aimed solely at the media and is for information purposes only. The opinions expressed here are the views of the author and do not constitute investment advice. This is not a recommendation to purchase, sell or subscribe to financial instruments, an offer to sell investment funds or an offer of financial services. This press release is as dated. They do not necessarily represent the views of any company within the AXA Investment Managers Group and may be subject to change without notice. This does not constitute a Financial Promotion as defined by the Financial Conduct Authority. This is for information purposes only. No financial decisions should be made on the basis of the information provided. Past performance is not necessarily representative of future results: performance is not constant over time and the value of investments may fall as well as rise.

Not for Retail distribution: This press release is intended exclusively for Professional, Institutional or Wholesale Clients / Investors only, as defined by applicable local laws and regulation. Circulation must be restricted accordingly.

The value/returns are subject to fluctuations of the exchange rate that can impact their performance.

Information about the AXA IM Alts staff teams is only informative. We do not guarantee the fact that staff remain employed by AXA Investment Managers or its affiliates and exercise or continue to exercise in AXA IM Alts teams.

This document is aimed solely at the media and is for information purposes only. The opinions expressed here are the views of the author and do not constitute investment advice. This press release is as dated. They do not necessarily represent the views of any company within the AXA Investment Managers Group and may be subject to change without notice.

This press release should not be regarded as an offer, solicitation, invitation, or recommendation to subscribe for any investment service or product and is provided for information purposes only. No financial decisions should be made on the basis of information provided.

This press release does not constitute on the part of AXA Investment Managers a solicitation or investment, legal or tax advice. This material does not contain sufficient information to support an investment decision.

Due to its simplification, this document is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee forecasts made will come to pass. Data, figures, declarations, analysis, predictions, and other information in this document is provided based on our state of knowledge at the time of creation of this document. Whilst every care is taken, no representation or warranty (including liability towards third parties), express or implied, is made as to the accuracy, reliability or completeness of the information contained herein. Reliance upon information in this material is at the sole discretion of the recipient.

Issued in the UK by AXA Investment Managers UK Limited, which is authorised and regulated by the Financial Conduct Authority in the UK. Registered in England and Wales No: 01431068. Registered Office: 22 Bishopsgate London EC2N 4BQ
In other jurisdictions, this document is issued by AXA Investment Managers SA's affiliates in those countries.